Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (21-30 of 222) with videos related to

Pageof 23
Sort By:
Trends in Cancer|October 8, 2018
Synthetic Lethality and Cancer - Penetrance as the Major BarrierColm J Ryan, Ilirjana Bajrami, Christopher J Lord
Cancer Discovery|November 14, 2012
The promise of combining inhibition of PI3K and PARP as cancer therapyFarah L Rehman, Christopher J Lord, Alan Ashworth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2010
Therapeutic targeting of the DNA mismatch repair pathwaySarah A Martin, Christopher J Lord, Alan Ashworth
Nature Reviews. Clinical Oncology|October 20, 2010
Synthetic lethal approaches to breast cancer therapyFarah L Rehman, Christopher J Lord, Alan Ashworth
Cancer Discovery|March 4, 2018
Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast CancerRachael Natrajan, Andrew N J Tutt, Christopher J Lord
Nature Reviews. Drug Discovery|June 30, 2007
Utilizing RNA interference to enhance cancer drug discoveryElizabeth Iorns, Christopher J Lord, Nicholas Turner, et al.
Annual Review of Medicine|October 24, 2014
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitorsChristopher J Lord, Andrew N J Tutt, Alan Ashworth
Seminars in Cancer Biology|November 8, 2019
Translational genomics of ovarian clear cell carcinomaSaira Khalique, Christopher J Lord, Susana Banerjee, et al.
Cancer Treatment and Research|November 17, 2023
Exploiting Cancer Synthetic Lethality in Cancer-Lessons Learnt from PARP InhibitorsStephen J Pettitt, Colm J Ryan, Christopher J Lord
Nature|May 6, 2026
Two decades of PARP inhibitor synthetic lethality in cancerChristopher J Lord, Andrew N J Tutt, Alan Ashworth
Pageof 23

Showing results (21-30 of 222) with videos related to

Sort By:
Pageof 23
Trends in Cancer|October 8, 2018
Synthetic Lethality and Cancer - Penetrance as the Major BarrierColm J Ryan, Ilirjana Bajrami, Christopher J Lord
Cancer Discovery|November 14, 2012
The promise of combining inhibition of PI3K and PARP as cancer therapyFarah L Rehman, Christopher J Lord, Alan Ashworth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2010
Therapeutic targeting of the DNA mismatch repair pathwaySarah A Martin, Christopher J Lord, Alan Ashworth
Nature Reviews. Clinical Oncology|October 20, 2010
Synthetic lethal approaches to breast cancer therapyFarah L Rehman, Christopher J Lord, Alan Ashworth
Cancer Discovery|March 4, 2018
Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast CancerRachael Natrajan, Andrew N J Tutt, Christopher J Lord
Nature Reviews. Drug Discovery|June 30, 2007
Utilizing RNA interference to enhance cancer drug discoveryElizabeth Iorns, Christopher J Lord, Nicholas Turner, et al.
Annual Review of Medicine|October 24, 2014
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitorsChristopher J Lord, Andrew N J Tutt, Alan Ashworth
Seminars in Cancer Biology|November 8, 2019
Translational genomics of ovarian clear cell carcinomaSaira Khalique, Christopher J Lord, Susana Banerjee, et al.
Cancer Treatment and Research|November 17, 2023
Exploiting Cancer Synthetic Lethality in Cancer-Lessons Learnt from PARP InhibitorsStephen J Pettitt, Colm J Ryan, Christopher J Lord
Nature|May 6, 2026
Two decades of PARP inhibitor synthetic lethality in cancerChristopher J Lord, Andrew N J Tutt, Alan Ashworth
Pageof 23